Share on StockTwits

Epizyme (NASDAQ:EPZM) announced its earnings results on Wednesday. The company reported ($0.40) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.50) by $0.10, reports. The company had revenue of $9.50 million for the quarter, compared to the consensus estimate of $7.59 million.

Shares of Epizyme (NASDAQ:EPZM) opened at 35.02 on Wednesday. Epizyme has a 52 week low of $18.10 and a 52 week high of $42.71. The stock has a 50-day moving average of $31.27 and a 200-day moving average of $27.05. The company’s market cap is $1.152 billion.

A number of analysts have recently weighed in on EPZM shares. Analysts at HC Wainwright raised their price target on shares of Epizyme from $40.00 to $45.00 in a research note on Wednesday. They now have a “buy” rating on the stock. On a related note, analysts at Zacks downgraded shares of Epizyme from an “outperform” rating to a “neutral” rating in a research note on Thursday, August 7th. They now have a $36.80 price target on the stock. Finally, analysts at Wainwright initiated coverage on shares of Epizyme in a research note on Tuesday, July 15th. They set a “buy” rating and a $40.00 price target on the stock.

In other Epizyme news, EVP Robert A. Copeland sold 20,000 shares of Epizyme stock on the open market in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $29.42, for a total value of $588,400.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.